BioHarvest Sciences' Saffron Composition Advances to Stage 2, Securing $1.125M Development Contract
BHST is trading near its 52-week low of $3.57 (3.9% above the low).
Summary
BioHarvest Sciences announced the successful completion of Stage 1 development for its saffron composition, advancing the program to Stage 2 under a multi-stage development agreement valued at $1.125 million. This milestone validates the company's Botanical Synthesis platform for creating sustainable cell banks from scarce botanicals like saffron, which has significant market demand in nutraceutical and culinary sectors. The company also retains a 25% ownership stake in the saffron composition, providing future commercial manufacturing royalties. This development is a material positive for the small-cap company, demonstrating progress in its CDMO business model and opening up a new revenue stream beyond the recently announced fragrance contract. Investors will watch for further updates on Stage 2 progress and potential commercialization timelines for this high-value botanical.
At the time of this announcement, BHST was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $87M. The 52-week trading range was $3.57 to $12.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.